Roche Gets Priority Review for Immunotherapy Drug Tecentriq – Yahoo Finance
Counsel & Heal |
Roche Gets Priority Review for Immunotherapy Drug Tecentriq
Yahoo Finance Roche Holding AG's RHHBY Genentech announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq, for the treatment of patients suffering from … FDA Speeds Up Review Of Roche's Immunotherapy Drug Tecentriq For Bladder Cancer |
